Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU8KGB)

• Drug Name: SBB007833 Drug Info
• Synonyms: NSC 10120; NSC 105303; NSC 170724

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 672296
  CAS Number: CAS 22568-48-5
  TTD Drug ID: DMU8KGB

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostamatinib	DM6AUHV	Immune thrombocytopenic purpura	3B64.13	Approved	[2]
Fostamatinib disodium	DM3274D	Thrombocytopenia	3B64	Phase 3	[3]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[4]
TAK-659	DMJH3U0	Diffuse large B-cell lymphoma	2A81	Phase 2	[5]
GS-9876	DM9Q2B6	Cutaneous lupus erythematosus	EB5Z	Phase 2	[6]
GS-9973	DMKWCTR	Acute myeloid leukaemia	2A60	Phase 2	[7]
HM43239	DMV1SDA	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
SKI-O-703	DMTSKXR	Rheumatoid arthritis	FA20	Phase 1	[6]
PRT6207	DMP5CLY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
GSK2646264	DMQOM5V	Cutaneous lupus erythematosus	EB5Z	Phase 1	[10]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[11]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[11]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[12]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[14]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[14]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[6]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[10]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[15]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Company report (Portola Pharmaceuticals)
• [5] J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
• [8] Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
• [9] Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [13] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [16] Clinical pipeline report, company report or official report of Turning Point Therapeutics.